Display options
Cite
Deshane J, Alvarez RD, Siegal GP. Eradication of c-erbB-2-Positive Ovarian Cancer Cells Mediated by Intracellular Expression of Anti-c-erbB-2 Antibody. Methods Mol Med. 2001;39:757-68doi: 10.1385/1-59259-071-3:757.
Deshane, J., Alvarez, R. D., & Siegal, G. P. (2001). Eradication of c-erbB-2-Positive Ovarian Cancer Cells Mediated by Intracellular Expression of Anti-c-erbB-2 Antibody. Methods in molecular medicine, 39757-68. https://doi.org/10.1385/1-59259-071-3:757
Deshane, J, et al. "Eradication of c-erbB-2-Positive Ovarian Cancer Cells Mediated by Intracellular Expression of Anti-c-erbB-2 Antibody." Methods in molecular medicine vol. 39 (2001): 757-68. doi: https://doi.org/10.1385/1-59259-071-3:757
Deshane J, Alvarez RD, Siegal GP. Eradication of c-erbB-2-Positive Ovarian Cancer Cells Mediated by Intracellular Expression of Anti-c-erbB-2 Antibody. Methods Mol Med. 2001;39:757-68. doi: 10.1385/1-59259-071-3:757. PMID: 21340837.
Copy Download .nbib Format: NLM
Share it on

Methods Mol Med. 2001;39:757-68. doi: 10.1385/1-59259-071-3:757.

Eradication of c-erbB-2-Positive Ovarian Cancer Cells Mediated by Intracellular Expression of Anti-c-erbB-2 Antibody.

Methods in molecular medicine

J Deshane, R D Alvarez, G P Siegal

Affiliations

  1. Departments of Pathology, University of Alabama, Birmingham, AL.

PMID: 21340837 DOI: 10.1385/1-59259-071-3:757

Abstract

Overexpression of erbB-2 is important in the pathogenesis of a variety of human neoplasms. Overexpression of the erbB-2 gene product has been associated with poor clinical prognosis with respect to malignancies originating in the ovary, breast, gastrointestinal tract, salivary gland, and lung (1-4) and has led to the development of several therapeutic strategies to target tumor cells exhibiting increased surface levels of erbB-2. Monoclonal antibodies that exhibit high-affinity binding to the extracellular domains of the erbB-2 protein have been developed (5,6). Several studies have demonstrated that a subset of these antibodies can elicit growth inhibition of erbB-2 overexpressing cells both in vitro and in vivo (5,6). Antitumor therapies directed at erbB-2 have also been developed utilizing targeted immunotoxins (7). Gene-therapy strategies such as antisense technology has been widely used in these areas of research to achieve selected knockout of genes both at transcriptional or posttranscriptional levels (8-10). Recombinant fusion proteins consisting of various bacterial toxins selectively targeted to the tumor by virtue of single-chain anti-erbB-2 antibody (sFv) moieties has also been utilized in this context (7).

Publication Types